Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR7280
- Development stage
- Phase 3
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SHR7280 is an oral, non-peptide small molecule gonadotropin-releasing hormone (GnRH) antagonist developed by Jiangsu Hengrui Medicine. It acts by competitively binding to GnRH receptors in the anterior pituitary gland, thereby inhibiting GnRH receptor signaling and suppressing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to a reduction in sex hormone levels such as estrogen and progesterone. SHR7280 is being investigated for the treatment of sex hormone-dependent disorders including endometriosis, menorrhagia with uterine fibroids, female infertility, and prostate cancer.
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on SHR7280.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR7280.